Pharmaceuticals Sector

Sumitomo Chemical’s pharmaceuticals business began in 1935 with the construction of a modern manufacturing plant based on its advanced organic synthesis technology, which enabled integrated production, from raw materials to finished pharmaceutical products. At present, the company is developing the Sector through Sumitomo Pharma Co., Ltd., engaged in the prescription pharmaceuticals business, and Nihon Medi-Physics Co., Ltd., engaged in the diagnostic pharmaceuticals business.

Sumitomo Pharma Co., Ltd.

  • Pharmaceutical research

In order to deliver innovative and useful pharmaceuticals and healthcare solutions to people in Japan and around the world, we devote all our efforts to R&D and providing information on pharmaceuticals with the aim of improving customer satisfaction.
With a focus on the Psychiatry & Neurology and Oncology disease areas, where unmet medical needs are high, we make active efforts for research and development of pharmaceuticals, regenerative medicine/cell therapy, non-pharmaceutical products, and otherwise. In other areas (women’s health issues, urological diseases, diabetes, rare diseases, infectious diseases), too, we tap into assets at hand and make steady R&D efforts to deliver solid value to patients.
We have established strong business foundations in Japan, the United States, and China, including local HQ, sales, and R&D functions.

Nihon Medi-Physics Co., Ltd.

  • Manufacturing of PET radiopharmaceuticals

Nihon Medi-Physics is the leading company in the highly specialized field of nuclear medicine in both diagnosis and therapy.
It offers a comprehensive range of functions from research and development to production, marketing and sales of radiopharmaceuticals used in diagnostic imaging procedures, such as SPECT for cerebral vascular disorders, dementia, cardiac diseases, and malignant tumors, as well as PET, which is considered useful for early detection of malignant tumors and large vessel vasculitis.
In the therapy field, it provides a radioactive seed for brachytherapy.
By bringing out further emerging potential and usefulness in nuclear medicine and molecular imaging procedures, Nihon Medi-Physics is moving steadily forward to materialize Theranostics (integration of therapeutics and diagnostics) concept in medical care practice, so that it can contribute to solving various issues that medical professional are currently confronting.